IL136122A0 - Combination of active principles, in particular of tetrahydropyridines and acetylcholinesterase inhibiting agents, for treating senile dementia such as alzheimer dementia - Google Patents

Combination of active principles, in particular of tetrahydropyridines and acetylcholinesterase inhibiting agents, for treating senile dementia such as alzheimer dementia

Info

Publication number
IL136122A0
IL136122A0 IL13612298A IL13612298A IL136122A0 IL 136122 A0 IL136122 A0 IL 136122A0 IL 13612298 A IL13612298 A IL 13612298A IL 13612298 A IL13612298 A IL 13612298A IL 136122 A0 IL136122 A0 IL 136122A0
Authority
IL
Israel
Prior art keywords
dementia
tetrahydropyridines
combination
active principles
inhibiting agents
Prior art date
Application number
IL13612298A
Other languages
English (en)
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9714322A external-priority patent/FR2771007B1/fr
Priority claimed from FR9714324A external-priority patent/FR2771006B1/fr
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of IL136122A0 publication Critical patent/IL136122A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL13612298A 1997-11-14 1998-11-09 Combination of active principles, in particular of tetrahydropyridines and acetylcholinesterase inhibiting agents, for treating senile dementia such as alzheimer dementia IL136122A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9714322A FR2771007B1 (fr) 1997-11-14 1997-11-14 Association de principes actifs pour le traitement de la demence senile du type alzheimer
FR9714324A FR2771006B1 (fr) 1997-11-14 1997-11-14 Association de principes actifs pour le traitement de la demence senile du type alzheimer
PCT/FR1998/002384 WO1999025363A1 (fr) 1997-11-14 1998-11-09 Association de principes actifs, notamment de tetrahydropyridines et d'agents inhibiteurs de l'acetylcholinesterase, pour le traitement de la demence senile du type alzheimer

Publications (1)

Publication Number Publication Date
IL136122A0 true IL136122A0 (en) 2001-05-20

Family

ID=26233932

Family Applications (2)

Application Number Title Priority Date Filing Date
IL13612298A IL136122A0 (en) 1997-11-14 1998-11-09 Combination of active principles, in particular of tetrahydropyridines and acetylcholinesterase inhibiting agents, for treating senile dementia such as alzheimer dementia
IL136122A IL136122A (en) 1997-11-14 2000-05-14 Compounds of active ingredients, especially inhibitors of tetrahydropyridines and acetylcholinesterase carriers, for the treatment of dementia in adults, such as Alzheimer's dementia

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL136122A IL136122A (en) 1997-11-14 2000-05-14 Compounds of active ingredients, especially inhibitors of tetrahydropyridines and acetylcholinesterase carriers, for the treatment of dementia in adults, such as Alzheimer's dementia

Country Status (27)

Country Link
EP (1) EP1030671A1 (ko)
JP (1) JP2001523642A (ko)
KR (1) KR100599350B1 (ko)
CN (1) CN1243540C (ko)
AU (1) AU743228B2 (ko)
BG (1) BG64819B1 (ko)
BR (1) BR9814035A (ko)
CA (1) CA2309966A1 (ko)
CO (1) CO4980891A1 (ko)
DZ (1) DZ2649A1 (ko)
EA (1) EA003255B1 (ko)
EE (1) EE04235B1 (ko)
HU (1) HUP0100098A3 (ko)
ID (1) ID24933A (ko)
IL (2) IL136122A0 (ko)
IS (1) IS5482A (ko)
MY (1) MY120461A (ko)
NO (1) NO20002450L (ko)
NZ (1) NZ504420A (ko)
OA (1) OA11464A (ko)
PL (1) PL194597B1 (ko)
SA (1) SA98190747B1 (ko)
SK (1) SK286040B6 (ko)
TR (1) TR200001262T2 (ko)
TW (1) TW585766B (ko)
UY (1) UY25247A1 (ko)
WO (1) WO1999025363A1 (ko)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2389937T1 (sl) 2002-06-14 2018-10-30 Toyama Chemical Co., Ltd, Farmacevtska sestava za izboljšanje možganske funkcije
ES2327914T3 (es) * 2002-08-07 2009-11-05 Novartis Ag Metodo para pronosticar la sensibilidad al tratamiento con ravastigmina basado en el genotipo apoe de pacintes con demencia.
CN1520818A (zh) * 2003-02-09 2004-08-18 山东绿叶天然药物研究开发有限公司 治疗老年性痴呆的胆碱酯酶抑制剂药物组合物
US8481565B2 (en) 2004-12-27 2013-07-09 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug
US9796672B2 (en) 2014-01-31 2017-10-24 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating neurodegenerative disease
MX2019013524A (es) * 2017-05-15 2020-02-10 Cognition Therapeutics Inc Composiciones para tratar enfermedades neurodegenerativas.
KR102224918B1 (ko) 2018-03-20 2021-03-09 (주)인벤티지랩 도네페질 및 메만틴을 포함하는 인지 장애 관련 질병의 예방 또는 치료용 약학적 복합 조성물 및 이의 제조 방법
WO2019182319A1 (ko) * 2018-03-20 2019-09-26 (주)인벤티지랩 인지 장애 관련 질병의 예방 또는 치료용 약학적 조성물의 제조 방법 및 이의 제조 방법으로 제조된 인지 장애 관련 질병의 예방 또는 치료용 약학적 조성물
CN109265391B (zh) * 2018-11-13 2021-11-19 枣庄学院 联苯多取代1,2,5,6-四氢吡啶化合物及其合成方法与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.
US5453428A (en) * 1991-02-14 1995-09-26 The Mount Sinai School Of Medicine Of The City Of New York Method and composition for the treatment of apathy-amotivation syndrome
PL185124B1 (pl) * 1995-03-06 2003-02-28 Interneuron Pharmaceuticals Zastosowanie cytykoliny oraz jej kompozycja do wytwarzania leku przeznaczonego do ochrony tkanki mózgowej
FR2736053B1 (fr) * 1995-06-28 1997-09-19 Sanofi Sa Nouvelles 1-phenylalkyl-1,2,3,6-tetrahydropyridines

Also Published As

Publication number Publication date
DZ2649A1 (fr) 2004-12-28
IL136122A (en) 2006-07-05
EE04235B1 (et) 2004-02-16
CA2309966A1 (en) 1999-05-27
NZ504420A (en) 2003-08-29
OA11464A (en) 2003-11-18
AU1160999A (en) 1999-06-07
BR9814035A (pt) 2000-09-26
TR200001262T2 (tr) 2001-01-22
SK286040B6 (sk) 2008-01-07
EP1030671A1 (fr) 2000-08-30
WO1999025363A1 (fr) 1999-05-27
EA200000412A1 (ru) 2000-12-25
PL194597B1 (pl) 2007-06-29
CN1285742A (zh) 2001-02-28
PL340500A1 (en) 2001-02-12
CN1243540C (zh) 2006-03-01
ID24933A (id) 2000-08-31
AU743228B2 (en) 2002-01-24
BG104428A (en) 2001-08-31
BG64819B1 (bg) 2006-05-31
KR20010032099A (ko) 2001-04-16
CO4980891A1 (es) 2000-11-27
NO20002450D0 (no) 2000-05-11
SK7112000A3 (en) 2000-10-09
EE200000290A (et) 2001-06-15
TW585766B (en) 2004-05-01
IS5482A (is) 2000-05-09
HUP0100098A3 (en) 2001-12-28
SA98190747B1 (ar) 2006-11-04
UY25247A1 (es) 2001-05-31
EA003255B1 (ru) 2003-02-27
JP2001523642A (ja) 2001-11-27
HUP0100098A2 (hu) 2001-07-30
NO20002450L (no) 2000-07-14
KR100599350B1 (ko) 2006-07-12
MY120461A (en) 2005-10-31

Similar Documents

Publication Publication Date Title
HUP0103920A3 (en) Methods and compositions for the prevention and treatment of anemia
IL125236A0 (en) Disinfecting compositions and processes for disinfecting surfaces
AU2001239052A1 (en) Compositions for prevention and treatment of dementia
IL125237A0 (en) Disinfecting compositions and processes for disinfecting surfaces
CA2258701A1 (en) Carboxamide derivatives of pyrrolidine, piperidine and hexahydroazepine for the treatment of thrombosis disorders
GB0011925D0 (en) Composition and method for preventing or alleviating migraine headaches
IL136122A0 (en) Combination of active principles, in particular of tetrahydropyridines and acetylcholinesterase inhibiting agents, for treating senile dementia such as alzheimer dementia
EP1162934A4 (en) COMPOSITIONS AND METHODS FOR PREVENTING PHOTOVAGENING
HUP0001629A3 (en) Method for treating plants and copperchelate containing compositions for it
IL131085A0 (en) The use of levobupivacaine or ropivacaine in treating migraine
EP1082122A4 (en) ISOFLAVONOIDS USEFUL IN THE TREATMENT AND PREVENTION OF MIGRAINE HEADACHE
HU9800396D0 (en) Pharmaceutical composition for treating dementia
EP1181308A4 (en) METHODS OF TREATING NEURONAL DEMENTIA ASSOCIATED WITH ATROPHY
ZA962636B (en) Compositions and process for treating hemangioma
AU5577101A (en) Enzymes useful for treating and methods for treating mps-vi and cells lines for producing such enzymes recombinantly
HUP0102995A3 (en) Agents and method for the protective treatment of wood
EP1246952A4 (en) COMPOSITION AND METHOD FOR TREATING METALS
EP0815867A4 (en) CELLS FOR THE TREATMENT OF DEMENTIA
EP0708638A4 (en) METHODS AND COMPOSITIONS FOR TREATING DEPRESSION AND OTHER PSYCHIATRIC DISEASES
ZA989955B (en) Combination of active ingredients for the treatment of senile dementia of the alzheimer type
HK1021314A1 (en) Formulation for the treatment and/or prophylaxis of dementia
ZA974390B (en) Carboxamide derivatives of pyrrolidine piperidine and hexahydroazepine for the treatment of thrombosis disorders.
HUP9602459A3 (en) Process and composition for preventing discolouration of maleicanhydride
SI0983237T1 (en) Chemical process for the reduction of 1-substituted -3-hydroxymethyl-4- (4-fluorophenyl)tetrahydropyridines
GB9909906D0 (en) Compositions and methods for treating effluent

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees